William Steinbach
Concepts (504)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspergillus fumigatus | 54 | 2021 | 102 | 19.530 |
Why?
| | Antifungal Agents | 92 | 2024 | 347 | 14.660 |
Why?
| | Fungal Proteins | 31 | 2024 | 118 | 9.820 |
Why?
| | Aspergillosis | 48 | 2020 | 122 | 9.210 |
Why?
| | Calcineurin | 29 | 2024 | 76 | 8.530 |
Why?
| | Echinocandins | 35 | 2017 | 64 | 4.920 |
Why?
| | Hyphae | 17 | 2018 | 32 | 4.850 |
Why?
| | Mycoses | 28 | 2023 | 152 | 4.400 |
Why?
| | Cell Wall | 17 | 2020 | 59 | 3.380 |
Why?
| | HSP90 Heat-Shock Proteins | 10 | 2016 | 56 | 3.280 |
Why?
| | Tacrolimus | 16 | 2024 | 60 | 2.650 |
Why?
| | Lipopeptides | 29 | 2017 | 62 | 2.570 |
Why?
| | Fungi | 12 | 2024 | 51 | 2.470 |
Why?
| | Candidiasis | 23 | 2022 | 113 | 2.460 |
Why?
| | Gene Expression Regulation, Fungal | 12 | 2019 | 51 | 2.400 |
Why?
| | Aspergillus | 15 | 2017 | 53 | 2.370 |
Why?
| | Drug Resistance, Fungal | 14 | 2023 | 34 | 2.310 |
Why?
| | Candidiasis, Invasive | 6 | 2024 | 11 | 2.290 |
Why?
| | Septins | 5 | 2017 | 20 | 2.280 |
Why?
| | Tacrolimus Binding Protein 1A | 8 | 2024 | 17 | 2.200 |
Why?
| | Hematopoietic Stem Cell Transplantation | 18 | 2023 | 606 | 2.110 |
Why?
| | Candida | 14 | 2022 | 63 | 1.960 |
Why?
| | Spores, Fungal | 7 | 2018 | 21 | 1.860 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 3 | 2020 | 50 | 1.770 |
Why?
| | beta-Glucans | 9 | 2022 | 23 | 1.740 |
Why?
| | Cryptococcus neoformans | 6 | 2023 | 26 | 1.690 |
Why?
| | Peptides, Cyclic | 14 | 2007 | 42 | 1.610 |
Why?
| | Pediatrics | 7 | 2018 | 292 | 1.600 |
Why?
| | Child | 57 | 2024 | 7157 | 1.460 |
Why?
| | Triazoles | 17 | 2024 | 115 | 1.460 |
Why?
| | Invasive Pulmonary Aspergillosis | 5 | 2017 | 12 | 1.450 |
Why?
| | Mannans | 6 | 2017 | 16 | 1.410 |
Why?
| | Humans | 144 | 2024 | 52336 | 1.400 |
Why?
| | Virulence | 11 | 2020 | 167 | 1.340 |
Why?
| | Phosphorylation | 8 | 2020 | 531 | 1.290 |
Why?
| | Mucormycosis | 5 | 2021 | 28 | 1.290 |
Why?
| | Fungemia | 8 | 2015 | 38 | 1.280 |
Why?
| | Myosin Type V | 2 | 2020 | 5 | 1.260 |
Why?
| | Microbial Sensitivity Tests | 16 | 2024 | 286 | 1.250 |
Why?
| | Mutation | 10 | 2020 | 1351 | 1.140 |
Why?
| | Chitin Synthase | 3 | 2011 | 6 | 1.060 |
Why?
| | Protein Processing, Post-Translational | 4 | 2017 | 158 | 1.060 |
Why?
| | Immunocompromised Host | 11 | 2020 | 123 | 1.030 |
Why?
| | Opportunistic Infections | 6 | 2017 | 56 | 0.990 |
Why?
| | Child, Preschool | 32 | 2024 | 4030 | 0.960 |
Why?
| | Calcium | 4 | 2019 | 375 | 0.910 |
Why?
| | Adolescent | 36 | 2024 | 6692 | 0.890 |
Why?
| | Azoles | 7 | 2020 | 28 | 0.880 |
Why?
| | Animals | 32 | 2023 | 13523 | 0.870 |
Why?
| | Stress, Physiological | 6 | 2019 | 186 | 0.870 |
Why?
| | Protein Multimerization | 3 | 2020 | 57 | 0.860 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2017 | 181 | 0.820 |
Why?
| | Amphotericin B | 12 | 2023 | 103 | 0.810 |
Why?
| | Amino Acid Sequence | 11 | 2021 | 591 | 0.810 |
Why?
| | Mice | 18 | 2023 | 5965 | 0.810 |
Why?
| | Pyrimidines | 11 | 2011 | 199 | 0.770 |
Why?
| | Chitin | 3 | 2011 | 7 | 0.750 |
Why?
| | Candida albicans | 7 | 2019 | 32 | 0.750 |
Why?
| | Proteome | 2 | 2020 | 170 | 0.740 |
Why?
| | Infant | 28 | 2024 | 3684 | 0.740 |
Why?
| | Virus Diseases | 2 | 2019 | 45 | 0.730 |
Why?
| | Prodrugs | 1 | 2021 | 35 | 0.730 |
Why?
| | ras Proteins | 2 | 2012 | 64 | 0.720 |
Why?
| | Respiratory Tract Infections | 2 | 2019 | 81 | 0.710 |
Why?
| | DNA, Fungal | 3 | 2017 | 43 | 0.700 |
Why?
| | COP-Coated Vesicles | 1 | 2020 | 8 | 0.680 |
Why?
| | Catalytic Domain | 3 | 2017 | 61 | 0.660 |
Why?
| | Cyclosporine | 8 | 2017 | 67 | 0.650 |
Why?
| | Morphogenesis | 2 | 2012 | 18 | 0.640 |
Why?
| | Male | 47 | 2024 | 26696 | 0.630 |
Why?
| | Drug Discovery | 2 | 2019 | 93 | 0.630 |
Why?
| | Disease Models, Animal | 8 | 2017 | 1484 | 0.620 |
Why?
| | Actins | 3 | 2018 | 117 | 0.610 |
Why?
| | Neoplasms | 9 | 2020 | 1305 | 0.610 |
Why?
| | Antigens, Fungal | 3 | 2022 | 20 | 0.610 |
Why?
| | Training Support | 1 | 2018 | 10 | 0.610 |
Why?
| | Protein Binding | 5 | 2020 | 680 | 0.600 |
Why?
| | Gene Deletion | 6 | 2017 | 276 | 0.600 |
Why?
| | Organ Transplantation | 5 | 2020 | 50 | 0.600 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 487 | 0.570 |
Why?
| | Ribosomal Proteins | 1 | 2017 | 24 | 0.570 |
Why?
| | Molecular Sequence Data | 8 | 2016 | 792 | 0.550 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 127 | 0.540 |
Why?
| | Protein Interaction Maps | 1 | 2017 | 28 | 0.540 |
Why?
| | Infant, Newborn | 21 | 2020 | 2826 | 0.530 |
Why?
| | Signal Transduction | 8 | 2016 | 1716 | 0.530 |
Why?
| | Aminoglycosides | 5 | 2010 | 18 | 0.530 |
Why?
| | Immunosuppressive Agents | 6 | 2022 | 243 | 0.520 |
Why?
| | Myosins | 1 | 2016 | 19 | 0.510 |
Why?
| | Protein Transport | 5 | 2018 | 183 | 0.490 |
Why?
| | Prospective Studies | 10 | 2022 | 2428 | 0.490 |
Why?
| | Hospitalization | 3 | 2019 | 732 | 0.480 |
Why?
| | Transcription Factors | 4 | 2019 | 574 | 0.480 |
Why?
| | Galactose | 6 | 2017 | 29 | 0.480 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2015 | 71 | 0.470 |
Why?
| | Microscopy, Fluorescence | 4 | 2020 | 149 | 0.460 |
Why?
| | Molecular Chaperones | 1 | 2015 | 78 | 0.460 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 374 | 0.450 |
Why?
| | Cell Division | 1 | 2015 | 291 | 0.450 |
Why?
| | Models, Biological | 2 | 2018 | 743 | 0.450 |
Why?
| | Sepsis | 2 | 2015 | 229 | 0.450 |
Why?
| | Drug Therapy, Combination | 8 | 2012 | 395 | 0.440 |
Why?
| | Promoter Regions, Genetic | 2 | 2013 | 474 | 0.440 |
Why?
| | Otitis Media | 3 | 2003 | 30 | 0.430 |
Why?
| | Treatment Outcome | 16 | 2024 | 5407 | 0.430 |
Why?
| | Scedosporium | 2 | 2003 | 4 | 0.430 |
Why?
| | Pathology, Molecular | 1 | 2013 | 28 | 0.420 |
Why?
| | Sensitivity and Specificity | 7 | 2022 | 879 | 0.420 |
Why?
| | Transcriptional Activation | 1 | 2013 | 128 | 0.410 |
Why?
| | Lysine | 1 | 2014 | 92 | 0.410 |
Why?
| | United States | 13 | 2023 | 5182 | 0.410 |
Why?
| | Internship and Residency | 3 | 2004 | 449 | 0.410 |
Why?
| | Lipoproteins | 4 | 2005 | 40 | 0.410 |
Why?
| | Genes, Fungal | 3 | 2010 | 31 | 0.400 |
Why?
| | Tubulin | 1 | 2013 | 22 | 0.400 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 146 | 0.380 |
Why?
| | Risk Factors | 14 | 2023 | 3872 | 0.380 |
Why?
| | Cell Membrane | 4 | 2017 | 245 | 0.370 |
Why?
| | Lung | 6 | 2016 | 502 | 0.360 |
Why?
| | Clostridium Infections | 2 | 2023 | 55 | 0.360 |
Why?
| | Cell Polarity | 1 | 2011 | 17 | 0.360 |
Why?
| | Neutropenia | 4 | 2020 | 115 | 0.350 |
Why?
| | Female | 29 | 2024 | 28105 | 0.350 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 1 | 0.340 |
Why?
| | Drug Therapy | 1 | 2010 | 44 | 0.340 |
Why?
| | Peptides | 4 | 2004 | 229 | 0.340 |
Why?
| | Microbial Viability | 3 | 2016 | 32 | 0.340 |
Why?
| | Green Fluorescent Proteins | 3 | 2017 | 89 | 0.340 |
Why?
| | Cations | 1 | 2010 | 9 | 0.330 |
Why?
| | Calcium-Transporting ATPases | 1 | 2010 | 13 | 0.330 |
Why?
| | Candidemia | 2 | 2023 | 8 | 0.330 |
Why?
| | Amino Acid Motifs | 3 | 2016 | 59 | 0.330 |
Why?
| | Protein Structure, Tertiary | 4 | 2015 | 252 | 0.330 |
Why?
| | Peptide Synthases | 2 | 2006 | 4 | 0.330 |
Why?
| | Clinical Trials as Topic | 6 | 2015 | 468 | 0.320 |
Why?
| | Mutant Proteins | 2 | 2020 | 37 | 0.310 |
Why?
| | Cross Infection | 3 | 2017 | 93 | 0.310 |
Why?
| | Golgi Apparatus | 2 | 2010 | 101 | 0.310 |
Why?
| | Biguanides | 2 | 2011 | 3 | 0.310 |
Why?
| | Genes, ras | 1 | 2008 | 43 | 0.300 |
Why?
| | Lung Diseases, Fungal | 2 | 2008 | 20 | 0.300 |
Why?
| | Homeostasis | 1 | 2010 | 206 | 0.300 |
Why?
| | Chromatography, Liquid | 3 | 2017 | 240 | 0.290 |
Why?
| | Anti-Bacterial Agents | 7 | 2020 | 801 | 0.290 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2019 | 98 | 0.290 |
Why?
| | Sequence Deletion | 3 | 2018 | 73 | 0.280 |
Why?
| | Meningitis, Cryptococcal | 1 | 2007 | 10 | 0.280 |
Why?
| | Binding Sites | 2 | 2019 | 379 | 0.280 |
Why?
| | Otolaryngology | 3 | 2004 | 61 | 0.280 |
Why?
| | Models, Molecular | 3 | 2017 | 352 | 0.280 |
Why?
| | Evolution, Molecular | 1 | 2008 | 95 | 0.280 |
Why?
| | Endocarditis | 2 | 2004 | 31 | 0.270 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 460 | 0.270 |
Why?
| | Polyenes | 2 | 2023 | 4 | 0.270 |
Why?
| | Proteomics | 2 | 2020 | 326 | 0.260 |
Why?
| | Gliotoxin | 1 | 2006 | 1 | 0.260 |
Why?
| | Lepidoptera | 2 | 2017 | 4 | 0.260 |
Why?
| | Biopsy | 2 | 2020 | 604 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 2 | 2017 | 250 | 0.250 |
Why?
| | Conserved Sequence | 2 | 2018 | 55 | 0.240 |
Why?
| | Incidence | 5 | 2018 | 1059 | 0.240 |
Why?
| | Protein Subunits | 2 | 2018 | 80 | 0.230 |
Why?
| | Time Factors | 6 | 2023 | 2957 | 0.230 |
Why?
| | Microtubules | 2 | 2018 | 39 | 0.230 |
Why?
| | Otitis Media with Effusion | 2 | 2004 | 16 | 0.230 |
Why?
| | Antibiotic Prophylaxis | 3 | 2020 | 61 | 0.220 |
Why?
| | Mitosporic Fungi | 1 | 2004 | 2 | 0.220 |
Why?
| | Otoscopy | 1 | 2004 | 4 | 0.220 |
Why?
| | Mycology | 1 | 2003 | 2 | 0.220 |
Why?
| | Medical Laboratory Personnel | 1 | 2003 | 5 | 0.220 |
Why?
| | Mycetoma | 1 | 2003 | 1 | 0.220 |
Why?
| | Sterols | 1 | 2023 | 8 | 0.220 |
Why?
| | Pulmonary Aspergillosis | 3 | 2015 | 5 | 0.220 |
Why?
| | Adult | 17 | 2023 | 14139 | 0.210 |
Why?
| | Crystallography, X-Ray | 2 | 2024 | 156 | 0.210 |
Why?
| | Clinical Competence | 2 | 2004 | 404 | 0.210 |
Why?
| | Bacteremia | 2 | 2020 | 90 | 0.210 |
Why?
| | Education, Medical, Continuing | 1 | 2003 | 72 | 0.210 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 91 | 0.210 |
Why?
| | Communicable Diseases, Emerging | 1 | 2003 | 13 | 0.210 |
Why?
| | Egtazic Acid | 2 | 2015 | 11 | 0.200 |
Why?
| | Cohort Studies | 7 | 2024 | 1532 | 0.200 |
Why?
| | Lactams, Macrocyclic | 2 | 2012 | 15 | 0.200 |
Why?
| | Ergosterol | 2 | 2023 | 10 | 0.200 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 185 | 0.200 |
Why?
| | Benzoquinones | 2 | 2012 | 33 | 0.200 |
Why?
| | Models, Statistical | 1 | 2004 | 230 | 0.200 |
Why?
| | Mucorales | 2 | 2020 | 12 | 0.200 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 85 | 0.190 |
Why?
| | Sequence Alignment | 3 | 2021 | 125 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1377 | 0.190 |
Why?
| | Educational Measurement | 1 | 2004 | 197 | 0.190 |
Why?
| | Colony Count, Microbial | 2 | 2016 | 61 | 0.190 |
Why?
| | Education, Medical | 1 | 2003 | 111 | 0.190 |
Why?
| | Mucor | 1 | 2021 | 8 | 0.190 |
Why?
| | Gene Expression | 2 | 2017 | 623 | 0.190 |
Why?
| | Osteomyelitis | 1 | 2003 | 125 | 0.190 |
Why?
| | Structure-Activity Relationship | 2 | 2024 | 406 | 0.180 |
Why?
| | Isoxazoles | 1 | 2021 | 15 | 0.180 |
Why?
| | Cryptococcosis | 2 | 2019 | 17 | 0.180 |
Why?
| | Bacteriological Techniques | 1 | 2001 | 41 | 0.180 |
Why?
| | Adenoviridae Infections | 1 | 2020 | 2 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2018 | 114 | 0.180 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2017 | 66 | 0.180 |
Why?
| | Dwarfism | 1 | 2000 | 4 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 1162 | 0.170 |
Why?
| | Bone Marrow Transplantation | 1 | 2001 | 113 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2001 | 66 | 0.170 |
Why?
| | Debridement | 1 | 2020 | 48 | 0.170 |
Why?
| | Transcription, Genetic | 2 | 2012 | 385 | 0.170 |
Why?
| | Retrospective Studies | 8 | 2020 | 6578 | 0.170 |
Why?
| | Cardiomegaly | 1 | 2000 | 57 | 0.170 |
Why?
| | Drug Resistance, Microbial | 4 | 2007 | 44 | 0.170 |
Why?
| | Salvage Therapy | 1 | 2020 | 136 | 0.170 |
Why?
| | Phenotype | 2 | 2018 | 799 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2001 | 98 | 0.170 |
Why?
| | Protein Structure, Secondary | 1 | 2020 | 71 | 0.170 |
Why?
| | Deafness | 1 | 2000 | 35 | 0.160 |
Why?
| | Cells, Cultured | 2 | 2023 | 1589 | 0.160 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2018 | 145 | 0.160 |
Why?
| | Biological Transport | 1 | 2020 | 158 | 0.160 |
Why?
| | Coccidioides | 1 | 2019 | 3 | 0.160 |
Why?
| | Mice, Inbred A | 1 | 2019 | 15 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 2 | 2012 | 484 | 0.160 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2020 | 191 | 0.160 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 44 | 0.160 |
Why?
| | Drug Design | 3 | 2024 | 121 | 0.160 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2019 | 35 | 0.160 |
Why?
| | Survival Rate | 4 | 2018 | 940 | 0.160 |
Why?
| | Calcium Signaling | 1 | 2019 | 52 | 0.150 |
Why?
| | Abnormalities, Multiple | 1 | 2000 | 167 | 0.150 |
Why?
| | Computer Simulation | 1 | 2020 | 290 | 0.150 |
Why?
| | International Cooperation | 2 | 2012 | 49 | 0.150 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2018 | 9 | 0.150 |
Why?
| | Curriculum | 1 | 2002 | 399 | 0.150 |
Why?
| | Kidney | 1 | 2023 | 708 | 0.150 |
Why?
| | Drug Interactions | 3 | 2010 | 205 | 0.150 |
Why?
| | Luminescent Proteins | 1 | 2018 | 51 | 0.150 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 42 | 0.150 |
Why?
| | Insulin Resistance | 1 | 2000 | 277 | 0.150 |
Why?
| | Respiratory Therapy | 1 | 2018 | 36 | 0.150 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2017 | 146 | 0.140 |
Why?
| | Molecular Sequence Annotation | 1 | 2017 | 28 | 0.140 |
Why?
| | Drug Synergism | 3 | 2011 | 148 | 0.140 |
Why?
| | Immunoprecipitation | 1 | 2017 | 57 | 0.140 |
Why?
| | Acetylation | 1 | 2018 | 96 | 0.140 |
Why?
| | Glucosyltransferases | 1 | 2017 | 6 | 0.140 |
Why?
| | Antibodies, Fungal | 1 | 2017 | 2 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2020 | 203 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2017 | 88 | 0.140 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2017 | 11 | 0.140 |
Why?
| | Protein Interaction Mapping | 1 | 2017 | 38 | 0.140 |
Why?
| | Mass Spectrometry | 1 | 2019 | 293 | 0.140 |
Why?
| | Immunoassay | 1 | 2017 | 23 | 0.140 |
Why?
| | Inpatients | 1 | 2019 | 205 | 0.140 |
Why?
| | Blood Proteins | 1 | 2017 | 84 | 0.140 |
Why?
| | Myeloid Cells | 1 | 2017 | 39 | 0.140 |
Why?
| | Logistic Models | 4 | 2023 | 920 | 0.140 |
Why?
| | Registries | 2 | 2012 | 580 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2000 | 315 | 0.130 |
Why?
| | Escherichia coli | 1 | 2017 | 187 | 0.130 |
Why?
| | Age Factors | 4 | 2018 | 1127 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 180 | 0.130 |
Why?
| | Candida glabrata | 1 | 2016 | 2 | 0.130 |
Why?
| | Protein Conformation | 1 | 2017 | 179 | 0.130 |
Why?
| | Phylogeny | 2 | 2015 | 234 | 0.130 |
Why?
| | Cyclophilin A | 1 | 2016 | 2 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2016 | 46 | 0.130 |
Why?
| | Moths | 1 | 2015 | 5 | 0.120 |
Why?
| | Substrate Specificity | 1 | 2016 | 198 | 0.120 |
Why?
| | Flucytosine | 2 | 2005 | 13 | 0.120 |
Why?
| | Drug Tolerance | 1 | 2015 | 60 | 0.120 |
Why?
| | Middle Aged | 9 | 2012 | 13014 | 0.120 |
Why?
| | Biomedical Research | 1 | 2018 | 256 | 0.120 |
Why?
| | Heat-Shock Response | 1 | 2015 | 29 | 0.120 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 10 | 0.120 |
Why?
| | Safety | 2 | 2005 | 79 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2015 | 70 | 0.110 |
Why?
| | Intracellular Space | 1 | 2014 | 24 | 0.110 |
Why?
| | Hematologic Neoplasms | 2 | 2017 | 106 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2005 | 35 | 0.110 |
Why?
| | Databases, Factual | 3 | 2007 | 706 | 0.110 |
Why?
| | Lung Diseases | 1 | 2015 | 86 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2022 | 594 | 0.110 |
Why?
| | Aged | 8 | 2012 | 10109 | 0.110 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 1903 | 0.110 |
Why?
| | Virulence Factors | 2 | 2022 | 80 | 0.110 |
Why?
| | Patient Selection | 3 | 2020 | 259 | 0.110 |
Why?
| | Acoustic Impedance Tests | 2 | 2004 | 8 | 0.100 |
Why?
| | Graft vs Host Disease | 3 | 2018 | 88 | 0.100 |
Why?
| | Drug Resistance, Multiple, Fungal | 1 | 2012 | 2 | 0.100 |
Why?
| | Epidemiologic Studies | 1 | 2012 | 22 | 0.100 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 150 | 0.100 |
Why?
| | Europe | 1 | 2012 | 87 | 0.100 |
Why?
| | Culture Media | 2 | 2010 | 98 | 0.100 |
Why?
| | Administration, Intravenous | 2 | 2024 | 73 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2014 | 326 | 0.100 |
Why?
| | Lipoylation | 1 | 2012 | 3 | 0.100 |
Why?
| | Serine C-Palmitoyltransferase | 1 | 2012 | 6 | 0.100 |
Why?
| | Cytosol | 1 | 2012 | 81 | 0.100 |
Why?
| | Palmitates | 1 | 2012 | 29 | 0.100 |
Why?
| | Infant, Premature, Diseases | 2 | 2017 | 94 | 0.090 |
Why?
| | Fever | 1 | 2012 | 112 | 0.090 |
Why?
| | Corneal Ulcer | 1 | 2011 | 4 | 0.090 |
Why?
| | Eye Infections, Fungal | 1 | 2011 | 20 | 0.090 |
Why?
| | Cytoplasm | 1 | 2011 | 97 | 0.090 |
Why?
| | Drug Dosage Calculations | 1 | 2011 | 11 | 0.090 |
Why?
| | Cell Shape | 1 | 2011 | 21 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2011 | 67 | 0.090 |
Why?
| | Acute Disease | 2 | 2002 | 374 | 0.090 |
Why?
| | Glycoside Hydrolases | 1 | 2010 | 18 | 0.090 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2017 | 18 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2017 | 1029 | 0.090 |
Why?
| | Young Adult | 5 | 2022 | 4319 | 0.080 |
Why?
| | Sorbitol | 1 | 2010 | 5 | 0.080 |
Why?
| | Cricetulus | 1 | 2010 | 104 | 0.080 |
Why?
| | CHO Cells | 1 | 2010 | 125 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 194 | 0.080 |
Why?
| | Saline Solution, Hypertonic | 1 | 2010 | 14 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 209 | 0.080 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2010 | 179 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 165 | 0.080 |
Why?
| | Administration, Oral | 2 | 2021 | 451 | 0.080 |
Why?
| | Fluconazole | 2 | 2009 | 34 | 0.080 |
Why?
| | Genome, Fungal | 2 | 2006 | 29 | 0.080 |
Why?
| | Fatal Outcome | 3 | 2004 | 196 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2023 | 3391 | 0.080 |
Why?
| | Disinfectants | 2 | 2011 | 11 | 0.080 |
Why?
| | Esophageal Diseases | 1 | 2009 | 21 | 0.080 |
Why?
| | Base Sequence | 1 | 2010 | 648 | 0.080 |
Why?
| | Drug Approval | 2 | 2006 | 46 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 404 | 0.070 |
Why?
| | Glucose | 1 | 2010 | 357 | 0.070 |
Why?
| | Fluorescent Dyes | 1 | 2008 | 91 | 0.070 |
Why?
| | Zinc Fingers | 1 | 2008 | 25 | 0.070 |
Why?
| | Intensive Care Units, Neonatal | 3 | 2005 | 136 | 0.070 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2008 | 2 | 0.070 |
Why?
| | Up-Regulation | 1 | 2010 | 462 | 0.070 |
Why?
| | Coronary Disease | 1 | 1988 | 152 | 0.070 |
Why?
| | Microbiological Techniques | 1 | 2007 | 8 | 0.070 |
Why?
| | Trans-Activators | 1 | 2008 | 138 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2007 | 943 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2006 | 6 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 236 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2008 | 141 | 0.070 |
Why?
| | Professional Misconduct | 1 | 2006 | 6 | 0.070 |
Why?
| | Infectious Disease Medicine | 2 | 2016 | 6 | 0.070 |
Why?
| | Neuroaspergillosis | 1 | 2006 | 1 | 0.070 |
Why?
| | Blood-Borne Pathogens | 1 | 2006 | 6 | 0.070 |
Why?
| | Mice, Inbred ICR | 1 | 2006 | 25 | 0.070 |
Why?
| | Cell Degranulation | 1 | 2006 | 4 | 0.060 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 12 | 0.060 |
Why?
| | Mice, Inbred DBA | 1 | 2006 | 47 | 0.060 |
Why?
| | Ethics, Research | 1 | 2006 | 39 | 0.060 |
Why?
| | Multigene Family | 1 | 2006 | 50 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2004 | 443 | 0.060 |
Why?
| | Regression Analysis | 2 | 2004 | 401 | 0.060 |
Why?
| | Radiography | 2 | 1985 | 470 | 0.060 |
Why?
| | Mast Cells | 1 | 2006 | 55 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2006 | 95 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 429 | 0.060 |
Why?
| | Itraconazole | 1 | 2005 | 38 | 0.060 |
Why?
| | Multivariate Analysis | 3 | 2019 | 590 | 0.060 |
Why?
| | Internet | 1 | 2007 | 262 | 0.060 |
Why?
| | Societies, Medical | 2 | 2016 | 200 | 0.060 |
Why?
| | Thiazoles | 1 | 2005 | 55 | 0.060 |
Why?
| | Down-Regulation | 1 | 2006 | 347 | 0.060 |
Why?
| | Radiographic Image Enhancement | 2 | 1984 | 29 | 0.060 |
Why?
| | Candidiasis, Chronic Mucocutaneous | 1 | 2004 | 2 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2004 | 2 | 0.060 |
Why?
| | Radiation Dosage | 2 | 1983 | 162 | 0.060 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 88 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2020 | 1201 | 0.060 |
Why?
| | Administration, Inhalation | 1 | 2004 | 115 | 0.060 |
Why?
| | Mice, Inbred BALB C | 2 | 2017 | 312 | 0.050 |
Why?
| | Serial Passage | 1 | 2023 | 4 | 0.050 |
Why?
| | Granulocytes | 1 | 2003 | 27 | 0.050 |
Why?
| | Meninges | 1 | 2003 | 13 | 0.050 |
Why?
| | Ascomycota | 1 | 2003 | 8 | 0.050 |
Why?
| | Brain Abscess | 1 | 2003 | 10 | 0.050 |
Why?
| | Administration, Topical | 1 | 2003 | 60 | 0.050 |
Why?
| | Infant, Premature | 3 | 2017 | 319 | 0.050 |
Why?
| | Fluoroscopy | 3 | 1984 | 50 | 0.050 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2003 | 51 | 0.050 |
Why?
| | Occupational Medicine | 1 | 1983 | 3 | 0.050 |
Why?
| | Cholesterol | 1 | 2023 | 156 | 0.050 |
Why?
| | Feces | 1 | 2023 | 154 | 0.050 |
Why?
| | Glucosamine | 1 | 1982 | 9 | 0.050 |
Why?
| | Otoscopes | 1 | 2002 | 1 | 0.050 |
Why?
| | Horse Diseases | 1 | 1982 | 19 | 0.050 |
Why?
| | Kinetics | 1 | 2023 | 623 | 0.050 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 1983 | 89 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 1436 | 0.050 |
Why?
| | Canada | 1 | 2002 | 104 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 34 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 1982 | 116 | 0.050 |
Why?
| | Immunotherapy | 1 | 2003 | 244 | 0.050 |
Why?
| | Viral Load | 1 | 2021 | 80 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 1981 | 66 | 0.050 |
Why?
| | Nitriles | 1 | 2021 | 53 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2001 | 16 | 0.040 |
Why?
| | Meningitis, Haemophilus | 1 | 2001 | 7 | 0.040 |
Why?
| | Anus, Imperforate | 1 | 2000 | 8 | 0.040 |
Why?
| | Adenoviridae | 1 | 2020 | 46 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2001 | 92 | 0.040 |
Why?
| | Data Collection | 1 | 2002 | 289 | 0.040 |
Why?
| | Testis | 1 | 1981 | 72 | 0.040 |
Why?
| | Nose | 1 | 2000 | 33 | 0.040 |
Why?
| | Ovary | 1 | 1981 | 107 | 0.040 |
Why?
| | Cytokines | 1 | 2003 | 625 | 0.040 |
Why?
| | Microcephaly | 1 | 2000 | 41 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 144 | 0.040 |
Why?
| | Pyridines | 1 | 2021 | 133 | 0.040 |
Why?
| | Cerebellar Cortex | 1 | 1980 | 5 | 0.040 |
Why?
| | Photofluorography | 1 | 1979 | 2 | 0.040 |
Why?
| | Goats | 1 | 1980 | 13 | 0.040 |
Why?
| | Rats | 1 | 2006 | 3202 | 0.040 |
Why?
| | Syndrome | 1 | 2000 | 247 | 0.040 |
Why?
| | Sheep | 1 | 1980 | 96 | 0.040 |
Why?
| | Respirovirus | 1 | 2019 | 1 | 0.040 |
Why?
| | Orthomyxoviridae | 1 | 2019 | 3 | 0.040 |
Why?
| | Metapneumovirus | 1 | 2019 | 5 | 0.040 |
Why?
| | Enterovirus | 1 | 2019 | 8 | 0.040 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2019 | 13 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 180 | 0.040 |
Why?
| | Cattle | 1 | 1980 | 207 | 0.040 |
Why?
| | Rhinovirus | 1 | 2019 | 24 | 0.040 |
Why?
| | Coronavirus | 1 | 2019 | 17 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2020 | 177 | 0.040 |
Why?
| | History, 21st Century | 1 | 2018 | 59 | 0.040 |
Why?
| | History, 20th Century | 1 | 2018 | 96 | 0.040 |
Why?
| | Disease Management | 1 | 2019 | 188 | 0.040 |
Why?
| | Complex Mixtures | 1 | 2017 | 7 | 0.040 |
Why?
| | K562 Cells | 1 | 2017 | 41 | 0.040 |
Why?
| | Farnesol | 1 | 2017 | 4 | 0.040 |
Why?
| | Proteolysis | 1 | 2017 | 102 | 0.030 |
Why?
| | HeLa Cells | 1 | 2017 | 263 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 1979 | 486 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 1543 | 0.030 |
Why?
| | Critical Illness | 1 | 2017 | 292 | 0.030 |
Why?
| | Cell Line | 1 | 2017 | 1045 | 0.030 |
Why?
| | Technology, Radiologic | 3 | 1983 | 16 | 0.030 |
Why?
| | Pneumonia | 1 | 2015 | 125 | 0.030 |
Why?
| | Prevalence | 2 | 2009 | 1007 | 0.030 |
Why?
| | Gestational Age | 2 | 2004 | 412 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 261 | 0.020 |
Why?
| | Germany, East | 2 | 1988 | 3 | 0.020 |
Why?
| | Cryptococcus | 1 | 2010 | 2 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1222 | 0.020 |
Why?
| | Food Microbiology | 1 | 2009 | 42 | 0.020 |
Why?
| | Food | 1 | 2009 | 66 | 0.020 |
Why?
| | Deoxycholic Acid | 1 | 2009 | 17 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2009 | 48 | 0.020 |
Why?
| | North America | 1 | 2009 | 73 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 134 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 220 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2015 | 636 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 372 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1044 | 0.020 |
Why?
| | Disease Notification | 1 | 2007 | 9 | 0.020 |
Why?
| | Survival Analysis | 1 | 2009 | 671 | 0.020 |
Why?
| | Recurrence | 1 | 2009 | 672 | 0.020 |
Why?
| | Hypercalcemia | 1 | 2007 | 34 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 15 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 31 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2006 | 73 | 0.020 |
Why?
| | RNA, Fungal | 1 | 2006 | 19 | 0.020 |
Why?
| | Referral and Consultation | 1 | 1988 | 292 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 104 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2007 | 137 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2007 | 187 | 0.020 |
Why?
| | Research | 1 | 2006 | 106 | 0.020 |
Why?
| | Disease Progression | 1 | 2009 | 870 | 0.020 |
Why?
| | Decision Theory | 1 | 1985 | 2 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1985 | 87 | 0.010 |
Why?
| | Transplantation Conditioning | 1 | 2005 | 93 | 0.010 |
Why?
| | Blood | 1 | 2004 | 26 | 0.010 |
Why?
| | Blood Glucose | 1 | 2006 | 471 | 0.010 |
Why?
| | Meningitis | 1 | 2003 | 24 | 0.010 |
Why?
| | Television | 2 | 1981 | 16 | 0.010 |
Why?
| | Hypertension | 1 | 1988 | 565 | 0.010 |
Why?
| | Immunophilins | 1 | 2003 | 1 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 1988 | 2268 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2006 | 1142 | 0.010 |
Why?
| | Brain Diseases | 1 | 2003 | 79 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 2004 | 86 | 0.010 |
Why?
| | Sirolimus | 1 | 2003 | 67 | 0.010 |
Why?
| | Horses | 1 | 1982 | 49 | 0.010 |
Why?
| | Prosthesis-Related Infections | 1 | 2004 | 107 | 0.010 |
Why?
| | Mediastinum | 1 | 1981 | 21 | 0.010 |
Why?
| | Diaphragm | 1 | 1981 | 33 | 0.010 |
Why?
| | Heart | 2 | 1981 | 357 | 0.010 |
Why?
| | Purkinje Cells | 1 | 1980 | 15 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1980 | 74 | 0.010 |
Why?
| | Mass Chest X-Ray | 1 | 1974 | 1 | 0.010 |
Why?
| | Quality Control | 1 | 1984 | 97 | 0.000 |
Why?
| | Electronics, Medical | 1 | 1977 | 4 | 0.000 |
Why?
| | Cardiac Volume | 1 | 1974 | 6 | 0.000 |
Why?
| | Methods | 1 | 1974 | 52 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1974 | 30 | 0.000 |
Why?
| | Physical Exertion | 1 | 1974 | 46 | 0.000 |
Why?
| | Heart Ventricles | 1 | 1974 | 268 | 0.000 |
Why?
| | Sex Factors | 1 | 1974 | 727 | 0.000 |
Why?
| | Heart Diseases | 1 | 1974 | 222 | 0.000 |
Why?
|
|
Steinbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|